FDA Approves SPIRIVA® HandiHaler® for the Reduction of COPD Exacerbations
Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Original Source of FDA Approves SPIRIVA® HandiHaler® for the Reduction of COPD Exacerbations
